Safety of Ketamine Treatment in Psychiatric Inpatients in Poland
Collects real-world safety data on ketamine in adults with treatment-resistant mental disorders.
Plain-language title generated from the registry record
Registry title: Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)
Key facts
- Where
- Gdansk, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT05565352, who can take part
Where in Poland
- Department of Psychiatry, Medical University of GdańskGdansk, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Gdansk
- Trial code
- NCT05565352
- Record updated
- 2 April 2025
- Original description
This observational registry aims to collect real-world data on ketamine use in psychiatric inpatients within a regional tertiary-reference center. The study evaluates the safety and tolerability of ketamine administration in individuals with treatment-resistant mental disorders, characterized by diverse comorbidities, heterogeneous disease courses, and variations in treatment responses based on illness stage and severity with a subset of patients with remitted-recurrent and treatment-resistant or chronic presentations.Read full original descriptionShow less
Ketamine Treatment Safety and Tolerability in Psychiatric Inpatient Care Delivered at Depatment of Psychiatry, Medical University of Gdańsk, Poland
This observational registry aims to collect real-world data on ketamine use in psychiatric inpatients within a regional tertiary-reference center. The study evaluates the safety and tolerability of ketamine administration in individuals with treatment-resistant mental disorders, characterized by diverse comorbidities, heterogeneous disease courses, and variations in treatment responses based on illness stage and severity with a subset of patients with remitted-recurrent and treatment-resistant or chronic presentations.
The registry is designed to systematically document adverse events, side effects, and patient-reported outcomes, providing a comprehensive assessment of both the short- and long-term effects of ketamine in psychopharmacology. By generating real-world evidence, this study shall contribute to a more nuanced understanding of ketamine's risk-benefit profile in clinical practice, particularly in subpopulations that are underrepresented in clinical trials. The findings prioritize the support for the refinement of treatment protocols and enhance patient safety in psychiatric care.
Inclusion: Diagnosis as provided by DSM-5 criteria:; Major depressive disorder (MDD),; Bipolar disorder (BD),; Anxiety disorder,; Obsessive-compulsive disorder (OCD),; Somatoform disorder,; Post-traumatic stress disorder (PTSD),; Dissociative disorder.
Exclusion: Hypersensitivity to ketamine; Uncontrolled hypertension; Other uncontrolled somatic diseases that may impact safety per the investigator's judgment; Pregnancy and lactation.